Danni Colledge

1.5k total citations
33 papers, 1.3k citations indexed

About

Danni Colledge is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Danni Colledge has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 28 papers in Hepatology and 11 papers in Infectious Diseases. Recurrent topics in Danni Colledge's work include Hepatitis B Virus Studies (31 papers), Hepatitis C virus research (26 papers) and Liver Disease Diagnosis and Treatment (11 papers). Danni Colledge is often cited by papers focused on Hepatitis B Virus Studies (31 papers), Hepatitis C virus research (26 papers) and Liver Disease Diagnosis and Treatment (11 papers). Danni Colledge collaborates with scholars based in Australia, United States and South Korea. Danni Colledge's co-authors include Stephen Locarnini, Timothy J. Shaw, Ros Edwards, William E. Delaney, Peter Revill, Vitina Sozzi, Margaret Littlejohn, Stephen Locarnini, Jordan J. Feld and Harriet C. Isom and has published in prestigious journals such as Hepatology, Journal of Virology and Gut.

In The Last Decade

Danni Colledge

33 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danni Colledge Australia 21 1.1k 1.0k 375 136 117 33 1.3k
Charlotte Hedskog United States 17 941 0.8× 1.0k 1.0× 457 1.2× 194 1.4× 40 0.3× 41 1.3k
V. Bichko United States 15 777 0.7× 723 0.7× 196 0.5× 193 1.4× 155 1.3× 35 1.0k
Christian Pichoud France 30 2.4k 2.1× 2.3k 2.3× 660 1.8× 108 0.8× 84 0.7× 54 2.6k
Matthew F. McCown United States 8 493 0.4× 290 0.3× 259 0.7× 226 1.7× 124 1.1× 10 730
L. Earnest-Silveira Australia 14 540 0.5× 515 0.5× 116 0.3× 122 0.9× 79 0.7× 19 719
L. O. Magnius Sweden 8 1.4k 1.2× 1.3k 1.3× 165 0.4× 48 0.4× 58 0.5× 12 1.4k
Amy K. Sheaffer United States 12 592 0.5× 245 0.2× 164 0.4× 107 0.8× 107 0.9× 15 732
Stephanie K. Ladner United States 5 723 0.6× 554 0.6× 221 0.6× 161 1.2× 59 0.5× 7 792
Stefan Seitz Germany 13 641 0.6× 517 0.5× 173 0.5× 165 1.2× 170 1.5× 30 952
Harvey M. Lieberman United States 10 793 0.7× 669 0.7× 126 0.3× 77 0.6× 29 0.2× 11 859

Countries citing papers authored by Danni Colledge

Since Specialization
Citations

This map shows the geographic impact of Danni Colledge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danni Colledge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danni Colledge more than expected).

Fields of papers citing papers by Danni Colledge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danni Colledge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danni Colledge. The network helps show where Danni Colledge may publish in the future.

Co-authorship network of co-authors of Danni Colledge

This figure shows the co-authorship network connecting the top 25 collaborators of Danni Colledge. A scholar is included among the top collaborators of Danni Colledge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danni Colledge. Danni Colledge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Hui, Stephen Locarnini, Darren Wong, et al.. (2021). Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. Journal of Hepatology. 76(1). 34–45. 21 indexed citations
3.
Sozzi, Vitina, Fang Shen, Jieliang Chen, et al.. (2018). In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease. Virology. 519. 190–196. 21 indexed citations
4.
5.
Jegaskanda, Sinthujan, Sang Hoon Ahn, Narelle Skinner, et al.. (2014). Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen. Journal of Virology. 88(18). 10412–10420. 43 indexed citations
6.
Li, Wenpeng, Nadia Warner, Vitina Sozzi, et al.. (2012). Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. Hepatology International. 7(2). 443–450. 10 indexed citations
7.
Shaw, Timothy J., Margaret Littlejohn, Danni Colledge, et al.. (2012). In vitro replication phenotype of a novel (−1G) hepatitis B virus variant associated with HIV co‐infection. Journal of Medical Virology. 84(8). 1166–1176. 10 indexed citations
8.
Wilson, Robert, Nadia Warner, Kathleen E. Ryan, et al.. (2011). The hepatitis B e antigen suppresses IL-1β-mediated NF-κB activation in hepatocytes. Journal of Viral Hepatitis. 18(10). e499–e507. 31 indexed citations
9.
Walsh, Renae, Peter Revill, Danni Colledge, et al.. (2011). Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology. 411(1). 132–141. 52 indexed citations
10.
Thompson, A., Danni Colledge, Peter Revill, et al.. (2008). Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antiviral Therapy. 14(6). 797–808. 54 indexed citations
11.
Revill, Peter, Margaret Littlejohn, Anna Ayres, et al.. (2007). Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS. 21(13). 1701–1710. 36 indexed citations
12.
Feld, Jordan J., Danni Colledge, Vitina Sozzi, et al.. (2007). The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Research. 76(2). 168–177. 122 indexed citations
13.
Bartholomeusz, Angeline, Michael J. Kuiper, P. Angus, et al.. (2006). 482 Molecular analysis of HBV polymerase mutations associated with dual adefovir and lamivudine resistance. Journal of Hepatology. 44. S179–S179. 2 indexed citations
14.
Locarnini, S., Timothy J. Shaw, Jonathan L. E. Dean, et al.. (2004). Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. Journal of Clinical Virology. 32(2). 113–121. 21 indexed citations
15.
Xiong, S., C. Westland, William E. Delaney, et al.. (2003). Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 182–182. 35 indexed citations
16.
Edwards, Ros, Timothy J. Shaw, Danni Colledge, et al.. (2003). Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology. 37(1). 27–35. 105 indexed citations
17.
Colledge, Danni, Timothy J. Shaw, S. Bowden, et al.. (2002). The purine nucleotide analogue LY582563 (mcc-478) inhibits replication of wild type and drug resistant hepatitis b virus. Journal of Hepatology. 36. 88–88. 3 indexed citations
18.
19.
Colledge, Danni. (1997). Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26(1). 216–225. 95 indexed citations
20.
Shaw, Timothy J., et al.. (1997). Lamivudine and penciclovir act synergistically as inhibitors of in vitro hepadnaviral replication penciclovir. Antiviral Research. 34(2). A64–A64. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte Hedskog Breakdown of academic impact, for papers by V. Bichko Breakdown of academic impact, for papers by Christian Pichoud Breakdown of academic impact, for papers by Matthew F. McCown Breakdown of academic impact, for papers by L. Earnest-Silveira Breakdown of academic impact, for papers by L. O. Magnius Breakdown of academic impact, for papers by Amy K. Sheaffer Breakdown of academic impact, for papers by Stephanie K. Ladner Breakdown of academic impact, for papers by Stefan Seitz Breakdown of academic impact, for papers by Harvey M. Lieberman
Rankless by CCL
2026